Stephen Mandel
Lone Pine Capital
Stephen Mandel Thermo Fisher Scientific Inc stake
total: 304
Lone Pine Capital TMO trades
- Total transactions:
- 7
- New positions:
- 2
- Sold out:
- 2
- Added:
- 1
- Reduced:
- 2
- Held since:
- 2022 Q1
- Held for:
- 4 quarters
- Latest activity:
- 2023 Q1
According to 2026 Q2 report, Stephen Mandel doesn't hold any Thermo Fisher Scientific Inc (TMO) shares. Lone Pine Capital has held TMO since at least 2013 Q2 with about 2.77M shares in our earliest available record. Stephen Mandel later completely sold out the position and invested in Thermo Fisher Scientific Inc again in 2022 Q1. Since at least 2013 Q2, Lone Pine Capital has made 6 more transactions.
When did Stephen Mandel sell Thermo Fisher Scientific Inc (TMO)?
Stephen Mandel sold off the entire Thermo Fisher Scientific Inc (TMO) position in 2023 Q1.
Estimated cost basis*
- Weighted AVG buy price:
- $569.74
- Weighted AVG sell price:
- $548.50
Stephen Mandel's historical trades in Thermo Fisher Scientific Inc
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q1
|
0.00%
|
0
|
$550.69
|
|
-100% (-587,696)
|
-3.09%
|
|
2022 Q4
|
3.09%
|
587,696
|
$550.69
|
$323,638,310
|
-33.62% (-297,630)
|
-1.54%
|
|
2022 Q3
|
4.23%
|
885,326
|
$507.19
|
$449,028,000
|
-5.04% (-46,966)
|
-0.22%
|
|
2022 Q2
|
4.77%
|
932,292
|
$543.28
|
$506,496,000
|
+79.04% (+411,583)
|
+2.11%
|
|
2022 Q1
|
1.83%
|
520,709
|
$590.65
|
$307,557,000
|
new
|
+1.83%
|
|
2013 Q3
|
0.00%
|
$84.63
|
-100% (-2,766,476)
|
|||
|
2013 Q2
|
1.18%
|
$84.63
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.